Gulf Pharmaceutical Industries (Julphar or the Company) has announced the appointment of Mr. Basel Ziyadeh as Chief Executive Officer (CEO), as the company drives its transformational growth strategy across the Middle East region and beyond. With a clear strategic direction in place and over 25 years of experience in the pharmaceutical industry, the new CEO, Mr. Basel is poised to continue this transformational journey and lead the company towards its vision of providing health solutions regionally and globally, while ensuring world-class care remains at the very heart of Julphar. Mr. Basel Ziyadeh will succeed Dr. Essam Mohamed as CEO, who has stepped down from the role, having joined in 2020, with over 25 years working in the healthcare sector.

Prior to his appointment at Julphar, Mr. Basel was CEO for Tabuk Pharmaceuticals, where he was instrumental in transforming the business, leading the company's substantial profitability expansion in addition to establishing key partnerships. Mr. Basel also held several leadership positions at Hikma Pharmaceuticals, serving across various functions and geographies over a 15-year period. During his tenure, he led the company's branded strategy formulation and execution in the MENA region after leading Hikma's full operations in the GCC and the Levant.

In addition, he also served as an advisor and Board Member for several pharmaceutical entities in Saudi Arabia, Egypt, Jordan, Sudan, Iraq and Lebanon. Mr. Basel holds a Bachelor's degree in Biological Sciences from University of Jordan and an MBA from American University of Beirut.